Angina (Angina Pectoris) – Pipeline Review, H1 2018


Angina (Angina Pectoris)


Angina pectoris is a term that describes chest pain caused by myocardial ischemia. It usually occurs on exertion and is relieved by rest. Angina generally is a symptom of coronary artery disease. In most severe cases, it occurs with minimal effort or at rest. Symptoms include anxiety, increased or irregular heart rate, paleness and cold sweat, and a feeling of doom. Risk factors include smoking, sedentary lifestyle, high blood fats or cholesterol, hypercholesterolemia.

Click here for sample report @


Major Key Players:

Angionetics Inc

Caladrius Biosciences Inc

Pohl-Boskamp GmbH & Co KG

Hemostemix Inc

ID Pharma Co Ltd

Juventas Therapeutics Inc

Kuhnil Pharmaceutical Co Ltd

Angina (Angina Pectoris) Industry Major Outlook

Pharmaceutical and Healthcare latest pipeline guide Angina (Angina Pectoris)    - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Angina (Angina Pectoris)   , complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Angina (Angina Pectoris) (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Angina (Angina Pectoris) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 1, 2, 2, 1, 3 and 2 respectively.

Angina (Angina Pectoris) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Angina (Angina Pectoris) - Competitive Analysis

Key players are making innovative developments in Angina (Angina Pectoris) industry.  The same will help in improving the market performance. Heavy investments are made by major players in the R&D sector


The pipeline guide provides a snapshot of the global therapeutic landscape of Angina (Angina Pectoris).

The pipeline guide reviews pipeline therapeutics for Angina (Angina Pectoris) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Angina (Angina Pectoris) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Angina (Angina Pectoris) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Angina (Angina Pectoris).


For Detailed Reading Please visit @


About Us

Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.

Contact Us:


Partner Relations & Marketing Manager

[email protected]

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)

Posted by on Tuesday March 13 2018, 8:34 AM EST. All trademarks acknowledged. Filed under Uncategorized. Comments and Trackbacks closed. Follow responses: RSS 2.0

Comments are closed

News Categories

Featured Press Releases

Log in